Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SINGAPORE EXCHANGE  >  Luye Pharma Group Ltd    LUYE   BMG5722Z1014

LUYE PHARMA GROUP LTD (LUYE)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

LUYE PHRM : Exercise Of The Call Option By Luye Biotech (Singapore) Pte Ltd Under The Investment Agreement To Acquire All The Shares Held By Biomedical Sciences Investment Fund Pte Ltd In The Issued Share Capital Of A-Bio Pharma Pte Ltd

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2011 | 12:35pm CEST

LUYE PHARMA GROUP LTD.

(INCORPORATED IN BERMUDA)

EXERCISE OF THE CALL OPTION BY LUYE BIOTECH (SINGAPORE) PTE LTD UNDER THE INVESTMENT AGREEMENT TO ACQUIRE ALL THE SHARES HELD BY BIOMEDICAL SCIENCES INVESTMENT FUND PTE LTD IN THE ISSUED SHARECAPITAL OF A-BIO PHARMA PTE LTD

Where capitalised terms are used in this announcement and not otherwise defined, such capitalised terms shall bear the same meanings as ascribed to them in the Company?s announcement dated

30 July 2010 in relation to the Strategic Investment in A-Bio Pharma Pte Ltd by Luye-Biotech

(Singapore) Pte Ltd.

The Board of Directors of Luye Pharma Group Ltd. (?Luye? or ?the Company?) is pleased to announce that Luye Biotech, a wholly-owned subsidiary of the Company, has exercised the Call Option under the Investment Agreement to acquire all of BMSIF?s shares comprising (i) one (1) ordinary share and (ii) 2,500,000 preference shares (Series B Preferred Shares) (collectively known as the ?Call Option Shares?) in A-Bio Pharma Pte Ltd (?A-Bio?) at a Option Consideration of S$2,750,000.

When the acquisition is completed, the Company will own 100% of the entire issued share capital of A-Bio through another wholly-owned subsidiary, Shandong Luye Pharmaceutical Co. Ltd.

The Option Consideration will funded by internal resources and is not expected to have any material impact on the net tangible assets per share and earnings per share of the Company for the current financial year ending 31 December 2011.

None of the Directors or controlling shareholders has any interest, directly or indirectly, in the transaction.

By Order of the Board

Liu Dianbo

Executive Chairman

Date: 25 July 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LUYE PHARMA GROUP LTD
06/11LUYE PHARMA : MDD drug starts phase III clinical trial
AQ
06/11LUYE PHARMA : Voluntary announcement - ansofaxine hydrochloride extended release..
PU
06/05LUYE PHARMA : Proxy form for special general meeting
PU
05/15LUYE PHARMA : AstraZeneca sells overseas rights to mental health drug Seroquel
AQ
05/11ASTRAZENECA : and Luye Pharma Group enter agreement for rights to Seroquel and S..
AQ
05/08LUYE PHARMA : to buy anti-psychotic drus at US$546m
AQ
05/08LUYE PHARMA : AstraZeneca sells rights for Seroquel to Luye Pharma for $538 mill..
RE
05/08AstraZeneca to Sell Seroquel License Rights to Luye Pharma for $538 Million
DJ
05/07ASTRAZENECA : AZ and Luye Pharma enter agreement for Seroquel
AQ
05/02LUYE PHARMA : Unaudited financial information of yantai luye
PU
More news
Financials ( CNY)
Sales 2018 4 419 M
EBIT 2018 1 274 M
Net income 2018 1 042 M
Finance 2018 1 641 M
Yield 2018 0,78%
P/E ratio 2018 20,79
P/E ratio 2019 18,22
EV / Sales 2018 4,95x
EV / Sales 2019 4,28x
Capitalization 23 519 M
Chart LUYE PHARMA GROUP LTD
Duration : Period :
Luye Pharma Group Ltd Technical Analysis Chart | LUYE | BMG5722Z1014 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 7,29  CNY
Spread / Average Target 0,96%
EPS Revisions
Managers
NameTitle
Dian Bo Liu Executive Chairman & Chief Executive Officer
Rong Bing Yang Vice Executive Chairman & President
Yuan Chong Liu Chief Financial Officer
You Xin Li Vice President, Head-Research & Development
Hui Xian Yuan Executive Director & Founding Member
Sector and Competitors